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EgyptAbstract Extensive allele diversity is observed in HLA associations with response to HCV com-
bined therapy (pegylated interferon + ribavitin) in different global ethnic populations. The aim
of the study is to assess the frequency and association of certain HLA-class I alleles in Egyptian
persons with persistent HCV and others with sustained viral response (SVR).
Material and methods: The study was a retrospective cohort study that included 246 HCV
patients who received combined therapy; 106 cases responded to treatment (SVR) and 140
individuals did not respond to treatment (persistent HCV infection). Both groups are subjected
to genotyping for HLA-class I.
Results: According to logistic regression analysis, Cw17 was considered as the most predictor
allele as it was the highest signiﬁcant allele (OR = 16.70; 95% CI: 2.64–105.58; P= 0.003), whereas
the presence of the HLA-B45 and HLA-B27 alleles has a 19.35-fold risk and 15.7 fold risk,
respectively of non-response to interferon therapy in chronic HCV patients (OR= 19.35; 95%
CI: 1.05–357.24; P= 0.04) and (OR= 15.69; 95% CI: 1.179–208.9; P= 0.04) can act also as high
predictor alleles, and the lowest signiﬁcant predictor allele was B44 (OR = 6.535; 95% CI: 1.55–
27.63; P= 0.01). The presence of the HLA-A alleles might have a limited role in prediction for
the non-responders, as the A32 was signiﬁcantly higher among the SVR patients, but, it cannot have
a predictor role (OR: 0.161, CI: 0.03–1.056, P= 0.049).
Conclusion: Cw17, HLA-B45, and HLA-B27 alleles can predict the nonresponders to HCV
combined therapy.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology.1. Introduction
Viral genotype, host genetic background and HLA class I- and
class II-alleles are associatedwith bothHCVdisease progression
and sustained response to therapy [8]. MHC class I molecules
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responses by presenting intracellular pathogen-derived peptides
to CD8+T cells and thus targeting infected cells for elimination
[9]. In HCV infection, recognition and elimination of infected
cells by cytotoxic T lymphocytes (CTLs) require the presenta-
tion of speciﬁc HCV antigens on the membrane of hepatocytes
in the context of HLA-A, -B and -C antigens. MHC class I mol-
ecules are highly polymorphic, but HLA-B is the most diverse
class I locus and the most polymorphic gene of the human gen-
ome [11]. Furthermore, HLA-B-restricted pathogen-derived
epitopes seem to be more frequently targeted by CD8+ T cells
than those presented onHLA-A.Additionally,HLA-B-dictated
T cell responses seem to be of higher magnitude [6,1] and have
been described to inﬂuence infectious disease course and
outcome.
For these reasons HLA-B alleles may be major determi-
nants of the effectiveness of immune responses against patho-
gens because the responses they elicit are dominant [9].
Previous studies demonstrate associations of genes encoding
HLA-class I antigens with the outcome of HCV infection.
Some associations are race and geography dependent. Inter-
feron therapy involves adverse effects; HLA studies will help
identifying responder/non responder markers that would help
select patients suitable for interferon therapy.
The relation between HCV viral load and HLA class I type
was previously studied by some Egyptian researchers [7]. The
aim of the present study is to assess the frequency and associa-
tion of certain HLA-class I alleles in Egyptian persons with per-
sistent HCV and others with sustained viral response (SVR).
2. Material and methods
2.1. Type of the study
The study was a retrospective cohort study of HCV infected
patients who received Peg-IFN plus ribavirin combined ther-
apy. Our study did not include healthy control group.
2.2. Subjects
The participants were recruited from the Liver Institute of
Cairo University, Egypt. All the participants in the present
study were from HCV patients who received combined therapy
in the Liver Institute of Cairo University. The participants
were divided according to standard criteria into:
- 140 chronic HCV patients (non-responder to Interferon
therapy).
- 106 resolved HCV cases: sustained viral response (SVR).
The aim of this study is to assess the frequency and associa-
tion of certain HLA class I alleles with viral clearance or per-
sistence of HCV infection after Peg-IFN plus ribavirin
therapy. Patients were treated by either pegylated or short-
acting interferon along with ribavirin according to Formann
et al. [3].
2.3. Laboratory investigations
The presence of HCV antibodies was determined by third-
generation enzyme linked immunosorbent assay ELISA;CTK-Bioteck-USA), liver function tests including ALT (ala-
nine transaminase), AST (aspartate transaminase), ALP (alka-
line phosphatase) and albumin were assayed using Olympus
auto analyzer AU400 (Olympus Diagnostica, Japan).
2.3.1. Detection of HCV–RNA by real time PCR and HCV
genotyping
Viral RNA was extracted from patient’s plasma using the
QIAamp Viral RNA Kit (Qiagen Hilden, Germany, Cat No.
52904) according to the manufacturer’s protocol. HCV RNA
was detected by commercially available Toyobo RNA-direct
real time PCR kit on SLAN Real Time PCR Detection Sys-
tem, LG Lifescience, Korea.
The HCV genotype was deﬁned by the reverse line probe
assay (INNO-LIPA v.1.0, innogenetics, Ghent, Belgium)
according to the manufacturer’s instruction.
2.3.2. HLA class I typing
Genomic DNA was extracted from peripheral blood mononu-
clear cells using the QIAmp DNA minikit (Qiagen) according
to the manufacturer’s instructions. HLA class I (A, B, and C)
typing was performed by sequence-speciﬁc oligonucleotide
probe protocols using LABType SSO Typing kit (ONE
LAMBDA,INC): LABType applies Luminex technology
to the reverse SSO DNA typing method according to the man-
ufacturer’s instructions.
2.4. Statistical analysis
Statistical analyses were carried out using ‘‘Statistical Package
for Social Science (SPSS) Inc., Chicago, IL, USA’’ (SPSS Ver-
sion 18). Qualitative data were expressed in number and per-
cent. Chi-square test ‘‘v2 ‘‘was used for comparing groups,
and Odds ratio (OR) was used to study the association between
the different alleles and the prognosis of HCV infections. Like-
lihood ratio was used if the expected values of >25 of the cells
are less than 5. Data that were signiﬁcant according to univar-
iate analysis were then entered in logistic regression analysis to
determine the predictable variable that can affect the response
to interferon treatment. We considered P-value to be signiﬁcant
at P< 0.05 with 95% conﬁdence interval (CI).3. Results
This study includes 246 patients with HCV infection who
received combined therapy; 106 resolved HCV (SVR) cases
and 140 chronic HCV cases (non responder). The age of par-
ticipants ranged between 20 and 50 years and the duration of
HCV infection ranged between 2 and 20 years.
The results of HCV genotyping revealed HCV genotype 4
(20%), and its subtypes 4c/4d (75%), 4e (1%) and 4h (4%).
No relationwas found betweenHCVgenotypes andHLA types.
In our study we detected 18 alleles at the A locus. The per-
cent of positive HLA-A alleles are shown in Table 1. There was
no signiﬁcant difference between the frequencies of the positive
alleles in non responder and in the SVR patients, except in
HLA-A*32. The frequency of HLA-A*32 was signiﬁcantly
higher in the SVR cases compared to the non responder cases.
In the present study, 29 alleles at the B locus were detected.
The percent of the positive HLA-B alleles are shown in Table 2.
Table 1 HLA-A allele frequencies of HCV infected subjects.
HCV patients (246) Likelihood ratio tests
Non-responder
(Chronic) (140)
Sustained Viral
Response
(SVR) (106)
Chi-square P-value
% %
A\01 33.0 38.0 0.416 0.519
A\02 40.7 29.2 0.373 0.541
A\03 15.7 17.0 1.748 0.186
A\11 7.1 6.6 0.225 0.635
A\23 9.3 8.5 0.402 0.526
A\24 13.6 14.2 0.011 0.915
A\26 6.4 6.6 0.373 0.541
A\29 4.3 6.6 0.096 0.756
A\30 22.1 18.9 0.115 0.735
A\31 2.9 1.9 0.276 0.599
A\32 3.6 10.4 3.859 0.04
A\33 8.6 9.4 0.266 0.606
A\34 7.0 9.0 0.783 0.376
A\36 0 1.9 3.580 0.058
A\66 2.1 1.9 0.018 0.893
A\68 11.4 14.2 0.838 0.360
A\69 6.4 1.9 2.911 0.088
A\74 2.9 1.9 0.820 0.365
Table 2 HLA-B allele frequencies of HCV infected subjects.
HCV patients (246) Likelihood ratio tests
Non-responder
(Chronic) (140)
Sustained Viral
Response
(SVR) (106)
Chi-square P-value
% %
B\07 6.4 3.4 3.737 .053
B\8 2.1 8.5 2.157 .142
B\13 3.6 3.8 1.818 .178
B\14 12.1 15.1 .049 .825
B\15 10.7 7.5 6.468 .011
B\18 4.3 2.8 4.705 .030
B\27 3.6 1.9 4.919 .027
B\35 17.9 17 0.03 0.858
B\37 0.7 2.8 .132 .716
B\38 8.6 8.5 3.527 .060
B\39 2.9 0.9 3.058 .080
B\40 2.1 1.9 .157 .692
B\41 21.4 15.1 .447 .504
B\42 2.1 0 .338 .561
B\44 10 5.7 7.135 .008
B\45 4.3 0.9 5.851 .016
B\47 0.7 0 5.772 .016
B\49 15 7.5 3.842 .050
B\50 6.4 7.5 1.528 .216
B\51 10 5.7 8.103 .004
B\52 11.4 12.3 .241 .623
B\53 2.9 8.5 2.075 .150
B\55 2.1 0.9 .043 .836
B\56 0.7 0.9 .162 .687
B\57 4.3 3.8 1.190 .275
B\58 5.7 4.7 .516 .473
B\73 0.7 1.9 .001 .975
B\78 0 0.9 2.037 .154
B\81 0.7 0 1.960 .162
Table 3 HLA-C allele frequencies of HCV infected subjects.
HCV patients (246) Likelihood ratio tests
Non-responder
(Chronic) (140)
Sustained Virus
Response
(SVR) (106)
Chi-square P-value
% %
Cw\01 2.1 0.9 0.576 0.448
Cw\02 4.3 7.5 1.196 0.274
Cw\03 7.1 5.7 5.046 .025
Cw\04 27.1 31.1 0.468 0.494
Cw\05 7.1 8.5 0.154 0.695
Cw\06 14.3 21.7 2.298 0.130
Cw\07 34.3 26.4 1.750 0.186
Cw\08 9.3 11.3 0.274 0.601
Cw\12 25.0 27.4 0.174 0.676
Cw\14 2.1 1.9 0.020 0.888
Cw\15 8.6 7.5 0.085 0.771
Cw\16 12.9 10.4 0.357 0.550
Cw\17 25.7 11.3 7.958 0.005
Cw\18 0.7 0.9 0.039 0.844
OR: Odds ratio; CI: Conﬁdence interval.
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niﬁcantly higher in SVR patients compared to the non respon-
der cases. Additionally, B\37 seemed to be associated with the
SVR cases by 4.1 times more than in the non responder cases,
even there was no statistical signiﬁcant difference detected.
Regarding the C allele, 14 alleles were identiﬁed at the C
locus. The percent of the positive HLA-C alleles are shown
in Table 3. The frequency of HLA-Cw\17 was signiﬁcantly
higher in non responder cases compared to the SVR cases,
but Odds ratio (OR) was less than 1. This means that the
absence of allele HLA-Cw\17 can be weakly used for testing
for the prognosis of the treatment.
According to the strength of the predictive value:
Logistic regressionwas used as shown in Table 4 to detect the
signiﬁcant predictor alleles for the response of HCV infected
cases to interferon treatment. According to logistic regression
analysis, HLA-A alleles might have a limited predictor role of
SVR amongHCV cases, as none of the A alleles have signiﬁcant
relation to the response to interferon treatment. Whereas, the
presence of the HLA-B45 and HLA-B27 alleles has a 19.35-fold
risk and 15.7 fold risk respectively of non-response to interferon
therapy in chronic HCV patients (OR = 19.35; 95% CI: 1.05–
357.24; P = 0.04) and (OR= 15.69; 95% CI: 1.179–208.9;
P= 0.04). But, Cw17 was considered as the most signiﬁcant
predictor allele as it was the highest signiﬁcant allele
(OR = 16.70; 95% CI: 2.64–105.58; P= 0.003). These three
alleles can act as the highest predictor alleles for the non-
responders to the combined therapy. The lowest signiﬁcant pre-
dictor allele was B44 (OR= 6.535; 95% CI: 1.55–27.63;
P= 0.01), with a constant 36.14.
4. Discussion
The mechanism of HCV pathogenesis remains elusive.
Interplay of HLA restricted T lymphocytes, antibody-secreting
Table 4 Logistic regression to predict non-responder (NR) to
interferon therapy in HCV patients by HLA-A, B and C alleles.
Alleles B coeﬃcient P-value OR 95% CI
Lower bound Upper bound
B45 2.963 0.04 19.353 1.048 357.236
Cw17 2.815 0.003 16.701 2.642 105.578
B27 2.753 0.04 15.695 1.179 208.936
Cw3 2.243 0.03 9.425 1.276 69.599
B51 2.222 0.006 9.225 1.878 45.313
B18 2.050 0.04 7.770 1.136 53.152
B47 1.984 0.004 7.271 1.858 28.461
B15 1.936 0.02 6.932 1.429 33.629
B44 1.877 0.01 6.535 1.545 27.629
OR: Odds ratio; CI: Conﬁdence interval, constant 36.139.
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response to viral infections. Effective presentation of viral anti-
gens to CD4 + T cells and CD8 + T cells by HLA class II and
class I molecules respectively, is the key regulation of optimum
immune response against viral infection, and further dictates
viral clearance or persistence [12]. HLA allele association with
interferon treatment response seems to differ for chronic HCV
infections in global populations. This can be attributed to dif-
ferences in the antigenic determinants of viruses and conse-
quently differences in the HLA molecules involved.
The aim of this study is to assess the inﬂuence of HLA-class
I on response to combination therapy for hepatitis C infection
and the predictive value of certain HLA class I alleles with sus-
ceptibilities to viral clearance or persistence after Peg-IFN plus
ribavirin therapy.
According to logistic regression analysis, Cw17 was consid-
ered as the most predictor allele of non response to combined
therapy in HCV, as it was the highest signiﬁcant allele
(OR = 16.70; 95% CI: 2.64–105.58; P = 0.003).
Cw17 belongs to group 2 HLA-C molecules which is recog-
nized by killer immunoglobulin like receptors of natural killer
cells KIR2DL1 [13]. The killer cell immunoglobulin-like recep-
tors (KIR) control the activation or inhibition of Natural killer
(NK) cells by recognition of speciﬁc HLA class I ligands, such
that target cell cytolysis occurs only when activating signals
overcome inhibitory signals. Inhibitory KIR2DL3/HLA-C1
is a relatively weak interaction, whilst inhibitory KIR2DL2/
HLA-C1 and KIR2DL1/HLA-C2 are relatively stronger and
therefore the observed correlation with outcome of HCV infec-
tion is consistent with the binding data in that weak HLA/KIR
interactions are more easily overcome by activating signals
than strong HLA and inhibitory KIR gene interaction [5]. In
a previous study of the same patient cohort, we demonstrated
that KIR2DL1/HLA-C2 was associated with persistent HCV
infection [4].
Regarding the B allele, according to logistic regression anal-
ysis, carriers of HLA-B\45 have a 19.35-fold risk of non
response to interferon therapy (OR= 19.35; 95% CI: 1.05–
357.24; P= 0.04) and can act as the highest predictor allele.
Also, carriers ofHLA-B\27 have a 15.7 fold risk of non response
to therapy (OR= 15.69; 95% CI: 1.179–208.9; P= 0.04),
whereas carriers of HLA-B\44 have a 6.535-fold risk of non
response to therapy (OR= 6.535; 95% CI: 1.55–27.63;P= 0.01) and can act as the lowest predictor allele. Similarly
Fanning et al. [2] demonstrated that persistent HCV infection
is associated with the presence of HLA-B\44. On the other
hand, a study conducted in Spain revealed the association of
HLAB44with responsiveness to interferon + ribavirin therapy
but not when interferon therapy is given alone in hepatitis C
with the viral non-1 genotype. [10].
In the current study, according to logistic regression analy-
sis, HLA-A alleles have a limited role in prediction of response
to treatment.
5. Conclusion
Certain class I alleles can predict the response to HCV treat-
ment, but a large scale study is needed to settle the prevalent
HLA alleles as well as other host genetic factors associated
with responsiveness in the Egyptian population in order to
select candidates for therapy and to reduce the exposure of
non responders to the adverse effects of interferon treatment.
Thus, Cw17, HLA-B45, and HLA-B27 alleles can predict the
response to HCV combined therapy.
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